Market closed
ImmunityBio/$IBRX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About ImmunityBio
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
Ticker
$IBRX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
672
Website
ImmunityBio Metrics
BasicAdvanced
$2.5B
-
-$0.88
-0.43
-
Price and volume
Market cap
$2.5B
Beta
-0.43
52-week high
$10.53
52-week low
$2.28
Average daily volume
6.5M
Financial strength
Current ratio
2.676
Quick ratio
2.219
Long term debt to equity
-135.661
Total debt to equity
-136.897
Interest coverage (TTM)
-2.41%
Management effectiveness
Return on assets (TTM)
-56.35%
Return on equity (TTM)
101.81%
Valuation
Price to revenue (TTM)
317.814
Price to book
-3.2
Price to tangible book (TTM)
-3.13
Price to free cash flow (TTM)
-5.368
Growth
Revenue change (TTM)
1,218.71%
Earnings per share change (TTM)
-15.40%
3-year revenue growth (CAGR)
164.33%
3-year earnings per share growth (CAGR)
1.45%
What the Analysts think about ImmunityBio
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for ImmunityBio stock.
ImmunityBio Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ImmunityBio Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ImmunityBio News
AllArticlesVideos
ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
Business Wire·1 week ago
ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
Business Wire·4 weeks ago
ImmunityBio: Making Its Next Strikes After Bladder Cancer Approval
Seeking Alpha·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for ImmunityBio stock?
ImmunityBio (IBRX) has a market cap of $2.5B as of February 23, 2025.
What is the P/E ratio for ImmunityBio stock?
The price to earnings (P/E) ratio for ImmunityBio (IBRX) stock is 0 as of February 23, 2025.
Does ImmunityBio stock pay dividends?
No, ImmunityBio (IBRX) stock does not pay dividends to its shareholders as of February 23, 2025.
When is the next ImmunityBio dividend payment date?
ImmunityBio (IBRX) stock does not pay dividends to its shareholders.
What is the beta indicator for ImmunityBio?
ImmunityBio (IBRX) has a beta rating of -0.43. This means that it has an inverse relation to market volatility.